UMARU LABAY-KAMARA: Open Payments
NPI 1396907945 · HUGHESVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,691 in 74 payments from 11 companies in 2025. Trend: 2023 $1,335 · 2024 $1,435 · 2025 $1,691
Food & beverage: $1,688Education: $4
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $364 |
| Neurocrine BioSciences, Inc. | 4 | $294 |
| Otsuka America Pharmaceutical, Inc. | 9 | $244 |
| E.R. Squibb & Sons, L.L.C. | 6 | $226 |
| Alkermes, Inc. | 13 | $193 |
| Teva Pharmaceuticals USA, Inc. | 5 | $107 |
| Vanda Pharmaceuticals Inc. | 3 | $95 |
| Janssen Pharmaceuticals, Inc | 2 | $81 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
Products named: VRAYLAR, INGREZZA, ABILIFY ASIMTUFII, BREYANZI, REXULTI, ARISTADA, FANAPT, COBENFY.
Industry payments across MD — which companies pay providers there.
